CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 276,326 shares, an increase of 91.4% from the May 31st total of 144,356 shares. Based on an average daily trading volume, of 459,271 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.0% of the company’s stock are sold short.

CalciMedica Stock Performance

CALC stock traded down $0.07 during midday trading on Thursday, reaching $0.97. 88,821 shares of the company were exchanged, compared to its average volume of 1,236,455. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20. The stock’s 50-day simple moving average is $0.74 and its 200 day simple moving average is $1.85. The company has a market cap of $15.29 million, a price-to-earnings ratio of -0.74 and a beta of 0.88.

Analysts Set New Price Targets

Separately, Oppenheimer dropped their price objective on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

Insider Activity at CalciMedica

In other news, Director Fred A. Middleton bought 248,972 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the purchase, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 41.55% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in shares of CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the period. Jane Street Group LLC purchased a new position in CalciMedica during the 4th quarter worth approximately $127,000. Envestnet Asset Management Inc. increased its position in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares during the period. Finally, PVG Asset Management Corp purchased a new stake in CalciMedica in the fourth quarter valued at approximately $302,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.